These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22750302)

  • 1. Expression of aspartoacylase (ASPA) and Canavan disease.
    Sommer A; Sass JO
    Gene; 2012 Sep; 505(2):206-10. PubMed ID: 22750302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.
    Kaul R; Balamurugan K; Gao GP; Matalon R
    Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
    Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
    Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
    Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
    J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspartoacylase gene knockout in the mouse: impact on reproduction.
    Surendran S; Szucs S; Tyring SK; Matalon R
    Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective.
    Wijayasinghe YS; Pavlovsky AG; Viola RE
    Biochemistry; 2014 Aug; 53(30):4970-8. PubMed ID: 25003821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of aspartoacylase: implications for Canavan disease.
    Hershfield JR; Pattabiraman N; Madhavarao CN; Namboodiri MA
    Brain Res; 2007 May; 1148():1-14. PubMed ID: 17391648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease.
    Kumar S; Biancotti JC; Matalon R; de Vellis J
    J Neurosci Res; 2009 Nov; 87(15):3415-27. PubMed ID: 19739253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
    Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
    Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
    Kaul R; Gao GP; Balamurugan K; Matalon R
    Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.
    George Priya Doss C; Zayed H
    Metab Brain Dis; 2017 Dec; 32(6):2105-2118. PubMed ID: 28879565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel splice site mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Rady PL; Penzien JM; Vargas T; Tyring SK; Matalon R
    Eur J Paediatr Neurol; 2000; 4(1):27-30. PubMed ID: 10701101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartoacylase is a regulated nuclear-cytoplasmic enzyme.
    Hershfield JR; Madhavarao CN; Moffett JR; Benjamins JA; Garbern JY; Namboodiri A
    FASEB J; 2006 Oct; 20(12):2139-41. PubMed ID: 16935940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
    Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
    Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical MRI findings in Canavan disease: a patient with a mild course.
    Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS
    Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.
    Surendran S
    Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease.
    Zeng BJ; Wang ZH; Ribeiro LA; Leone P; De Gasperi R; Kim SJ; Raghavan S; Ong E; Pastores GM; Kolodny EH
    J Inherit Metab Dis; 2002 Nov; 25(7):557-70. PubMed ID: 12638939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.